Lipocalin-2 Levels & Pediatric Ulcerative Colitis: Disease Severity Indicator

A newly identified biomarker in the blood shows promise for assessing the severity and extent of ulcerative colitis (UC) in children, according to research published in February 2026. Elevated levels of lipocalin-2 (LCN-2) appear to correlate with more extensive colon involvement and heightened disease activity in young patients newly diagnosed with UC. This finding could lead to earlier, more targeted interventions and a better understanding of how the condition manifests in a pediatric population.

Understanding Ulcerative Colitis in Children

Ulcerative colitis is a chronic inflammatory bowel disease (IBD) that causes inflammation and ulcers in the lining of the colon and rectum. Even as traditionally considered less common in children than adults, the incidence of pediatric UC has been rising in recent decades. Symptoms can include abdominal pain, diarrhea (often bloody), rectal bleeding, weight loss, and fatigue. Diagnosing UC in children can be challenging, as symptoms can overlap with other conditions, and endoscopic procedures – traditionally used for diagnosis – are invasive. The search for reliable, non-invasive biomarkers has been a priority for researchers.

The Role of Lipocalin-2, MMP-9, and the MMP-9/LCN-2 Complex

Researchers have been investigating several potential biomarkers for UC, including lipocalin-2 (LCN-2), matrix metalloproteinase-9 (MMP-9), and the complex formed when these two proteins bind together. LCN-2 is a protein involved in the innate immune response and has been shown to play a role in inflammation. MMP-9 is an enzyme that breaks down the extracellular matrix, contributing to tissue damage in inflammatory conditions. A study published in Digestive and Liver Disease, involving 32 children with newly diagnosed UC and 38 healthy controls, found significantly higher serum levels of all three – LCN-2, MMP-9, and the MMP-9/LCN-2 complex – in the UC patients compared to the control group. Source

The study, led by Giulia D’Arcangelo and colleagues, utilized ELISA to measure the levels of these biomarkers. Notably, LCN-2 demonstrated the strongest diagnostic performance in distinguishing between children with UC and healthy controls. Higher levels of LCN-2 and MMP-9 were also associated with more severe endoscopic disease, as measured by the Ulcerative Colitis Endoscopic Index of Severity (UCEIS), and with pancolitis – inflammation affecting the entire colon.

What the Findings Mean for Diagnosis and Monitoring

The findings suggest that LCN-2 could serve as a valuable tool for diagnosing UC in children, potentially reducing the need for early endoscopic procedures. The correlation between LCN-2 and MMP-9 levels and disease severity also indicates that these biomarkers could be used to monitor disease activity and assess response to treatment. For example, a decrease in LCN-2 levels during treatment might suggest that the therapy is effective. Yet, it’s crucial to remember that Here’s a single study, and further research is needed to validate these findings in larger, more diverse populations.

Beyond LCN-2: Broader Research into IBD Biomarkers

This research builds on a growing body of work exploring biomarkers in IBD. A study published in PubMed examined LCN2 levels in a larger group of IBD patients (both Crohn’s disease and UC) and healthy controls. Source This research found that LCN2 levels were significantly elevated in patients with active UC, and that LCN2 could be used as a marker of disease activity. The study also investigated the influence of genetic factors on LCN2 levels, finding that individuals with certain IL23R gene variants had lower LCN2 concentrations. This highlights the complex interplay between genetics, inflammation, and biomarker expression in IBD.

Another pilot study, presented at the European Crohn’s and Colitis Organisation (ECCO) conference, specifically focused on high serum lipocalin-2 expression in children with UC. Source While details are limited to the conference abstract, it reinforces the growing interest in LCN-2 as a potential biomarker in this population.

Limitations and Future Directions

The study by D’Arcangelo et al. Has several limitations. The sample size was relatively small, and the study population was limited to children with newly diagnosed UC. Further research is needed to determine whether these findings apply to children with established UC or to those with different subtypes of the disease. The study only measured biomarker levels at a single point in time. Longitudinal studies, which follow patients over time, are needed to assess how biomarker levels change with disease activity and treatment response. It’s also crucial to note that correlation does not equal causation. While the study found an association between LCN-2 levels and disease severity, it does not prove that LCN-2 directly causes or contributes to UC.

Ongoing and Planned Investigations

Researchers are now planning larger, multi-center studies to validate these findings and explore the potential clinical utility of LCN-2 as a biomarker for pediatric UC. These studies will likely involve more diverse populations and will include longitudinal follow-up to assess the dynamic changes in biomarker levels over time. There is also interest in investigating whether LCN-2 levels can be used to predict which patients are most likely to respond to specific treatments. Research is ongoing to understand the underlying mechanisms by which LCN-2 contributes to inflammation in UC, which could lead to the development of novel therapeutic targets.

The identification of LCN-2 as a potential biomarker represents a significant step forward in our understanding of pediatric UC. While more research is needed, this finding offers hope for improved diagnosis, monitoring, and treatment of this challenging condition. Parents and caregivers of children with suspected UC should consult with a qualified pediatric gastroenterologist for appropriate evaluation and management.